Search

Your search keyword '"Neodjuvant chemotherapy"' showing total 2 results
Start Over Descriptor "Neodjuvant chemotherapy" Topic biomarkers, tumor
2 results on '"Neodjuvant chemotherapy"'

1. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.

Author

Stojsic J, Stankovic T, Stojkovic S, Milinkovic V, Dinic J, Milosevic Z, Milovanovic Z, Tanic N, and Bankovic J

Subjects
Adenocarcinoma drug therapy, Adenocarcinoma metabolism, Adenocarcinoma pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, Loss of Heterozygosity, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Staging, PTEN Phosphohydrolase genetics, Phosphatidylinositol 3-Kinases metabolism, Polymerase Chain Reaction, Prognosis, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction, Survival Rate, TOR Serine-Threonine Kinases metabolism, Adenocarcinoma mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Squamous Cell mortality, Lung Neoplasms mortality, Neoadjuvant Therapy
Abstract

Lung cancer is the most common cause of neoplasia-related death worldwide. Accounting for approximately 80% of all lung carcinomas, the non-small cell lung carcinoma (NSCLC) is the most common clinical form with its two predominant histological types, adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Although surgical resection is the most favorable treatment for patients with NSCLC, relapse is still high, so neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In this study we examined whether some of the key molecules associated with the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways could have predictive and prognostic value for the NAC application. To that end we examined the expression status of PTEN, pAKT, pERK and loss of heterozygosity (LOH) of PTEN in two groups of NSCLC patients, those who received and those who did not receive NAC. LOH PTEN and low pERK expression is shown to be correlated with the longest survival of patients with SCC and ADC, respectively, who received NAC. These results point that the application of NAC is beneficial in the NSCLC patients with specific molecular alterations which could further help to improve constant search for the druggable molecular targets used in personalized therapy., (Copyright © 2014 Elsevier Inc. All rights reserved.)

Published
2015
Full Text
View/download PDF

2. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma

Author

Vedrana Milinkovic, Tijana Stanković, Zorica Milosevic, Jelena Dinić, Jelena Stojsic, Zorka Milovanovic, Sonja Stojković, Nikola Tanic, and Jasna Bankovic

Subjects
MAPK/ERK pathway, Oncology, Male, Lung Neoplasms, medicine.medical_treatment, Clinical Biochemistry, Loss of Heterozygosity, Polymerase Chain Reaction, Immunoenzyme Techniques, Phosphatidylinositol 3-Kinases, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, biology, TOR Serine-Threonine Kinases, Middle Aged, Prognosis, Neoadjuvant Therapy, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, Carcinoma, Squamous Cell, Adenocarcinoma, Female, Signal Transduction, medicine.medical_specialty, Non-small cell lung carcinoma, Pathology and Forensic Medicine, Internal medicine, medicine, Carcinoma, Biomarkers, Tumor, PTEN, Humans, Neoplasm Invasiveness, Lung cancer, Neodjuvant chemotherapy, Molecular Biology, Protein kinase B, PI3K/AKT/mTOR pathway, Neoplasm Staging, Chemotherapy, business.industry, PTEN Phosphohydrolase, medicine.disease, biology.protein, Neoplasm Grading, business, Proto-Oncogene Proteins c-akt, Follow-Up Studies
Abstract

Lung cancer is the most common cause of neoplasia-related death worldwide. Accounting for approximately 80\% of all lung carcinomas, the non-small cell lung carcinoma (NSCLC) is the most common clinical form with its two predominant histological types, adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Although surgical resection is the most favorable treatment for patients with NSCLC, relapse is still high, so neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In this study we examined whether some of the key molecules associated with the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways could have predictive and prognostic value for the NAC application. To that end we examined the expression status of PTEN, pAKT, pERK and loss of heterozygosity (LOH) of PTEN in two groups of NSCLC patients, those who received and those who did not receive NAG LOH PTEN and low pERK expression is shown to be correlated with the longest survival of patients with SCC and ADC, respectively, who received NAC. These results point that the application of NAC is beneficial in the NSCLC patients with specific molecular alterations which could further help to improve constant search for the druggable molecular targets used in personalized therapy. (C) 2014 Elsevier Inc. All rights reserved. Ministry of Education, Science and Technological Development of the Republic of Serbia {[}III41031]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results